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Background. Dengue virus is an emerging mosquito-borne flavivirus responsible for considerable morbidity and mortality 
worldwide. The Division of Intramural Research, National Institute of Allergy and Infectious Diseases of the US National Institutes 
of Health (NIH) has developed live attenuated vaccines to each of the 4 serotypes of dengue virus (DENV1–4). While overall levels of 
DENV neutralizing antibodies (nAbs) in humans have been correlated with protection, these correlations vary depending on DENV 
serotype, prevaccination immunostatus, age, and study site. By combining both the level and molecular specificity of nAbs to each 
serotype, it may be possible to develop more robust correlates that predict long-term outcome.
Methods. Using depletions and recombinant chimeric epitope transplant DENVs, we evaluate the molecular specificity and 
mapped specific epitopes and antigenic regions targeted by vaccine-induced nAbs in volunteers who received the NIH monovalent 
vaccines against each DENV serotype.
Results. After monovalent vaccination, subjects developed high levels of nAbs that mainly targeted epitopes that are unique 
(type-specific) to each DENV serotype. The DENV1, 2, and 4 monovalent vaccines induced type-specific nAbs directed to quater-
nary structure envelope epitopes known to be targets of strongly neutralizing antibodies induced by wild-type DENV infections.
Conclusions. Our results reported here on the molecular specificity of NIH vaccine–induced antibodies enable new strategies, 
beyond the absolute levels of nAbs, for determining correlates and mechanisms of protective immunity.
Keywords. dengue vaccine; flavivirus; neutralizing antibody; live attenuated vaccine.
Dengue viruses (DENVs) are mosquito-borne positive-sense 
RNA viruses in the flavivirus family. The 4 DENV serotypes 
(DENV1–4) co-circulate in tropical and subtropical regions [1]. 
A primary infection with a single serotype can be clinically in-
apparent, present as an acute febrile illness, or, rarely, progress to 
severe dengue hemorrhagic fever (DHF) [2, 3]. Primary infec-
tions stimulate DENV serotype cross-reactive neutralizing anti-
bodies (nAbs), which may provide transient protection against 
other serotypes, and durable serotype-specific (type-specific) 
antibodies implicated in long-term protection against rein-
fection by the homologous serotype [4–6]. Secondary DENV 
infections with new serotypes also present with symptoms that 
range from inapparent to severe DHF. However, the risk of DHF 
is increased in secondary infections, most likely because pre-
existing poorly neutralizing, cross-reactive antibodies increase 
the risk of severe disease through a phenomenon known as 
antibody-dependent enhancement [3]. Hence, leading DENV 
vaccine formulations are tetravalent to stimulate protective 
responses to all serotypes and to avoid the possibility of anti-
body-enhanced disease following vaccination.
The DENV envelope (E) protein is the main target of neu-
tralizing and protective antibodies (Abs) [7–9]. The ectodomain 
of E is composed of 3 domains: I, II, and III (EDI, EDII, and 
EDIII). Each DENV virion has 180 monomers of E that are 
organized into 90 dimers that cover the entire surface of the 
virus particle. The E proteins are arranged with icosahedral 
symmetry with each asymmetric unit containing portions of 3 
homodimers. Type-specific, neutralizing monoclonal antibod-
ies (MAbs) have been mapped from individuals infected with 
different DENV serotypes [10–14] that bind to complex quat-
ernary E protein epitopes displayed on intact virions but not on 
recombinant E protein monomers [10, 11, 15, 16]. Our recent 
studies have demonstrated that DENV type-specific epitopes 
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defined using human MAbs are also targeted by polyclonal 
serum nAbs in people exposed to primary infections [10, 11]. 
In the context of DENV vaccines, type-specific nAbs are likely 
to be critical for durable protection.
The National Institutes of Health (NIH) tetravalent live atten-
uated DENV vaccine is composed of DENV1–4 viruses with 
deletions in the 3′ untranslated region that result in attenuated 
strains [17–22]. In early-stage human clinical studies, monova-
lent and tetravalent formulations of the vaccine were immuno-
genic [19–24]. In a human infection model of DENV2, 1 dose 
of the tetravalent vaccine provided complete protection against 
this serotype [25]. The NIH vaccine is currently being evalu-
ated in phase 2 studies in Asia and a large phase 3 efficacy study 
in Brazil [26]. Recent studies with people exposed to natural 
DENV infections or live attenuated vaccines [27] indicate that 
the specificity, rather than total quantity, of nAbs is correlated 
with long-term protection. We hypothesized that a successful 
live DENV vaccine should elicit serotype-specific nAbs that are 
similar to those produced after natural primary infections. Here 
we report on the molecular specificity of nAbs induced by each 




Healthy volunteers were recruited by the Johns Hopkins 
Bloomberg School of Public Health Center for Immunization 
Research (CIR) located in Baltimore, Maryland, to receive one 
of the monovalent vaccines. The clinical protocol was reviewed 
and approved by the Joint Committee for Clinical Medicine and 
informed consent was obtained from each volunteer. Volunteers 
were recruited and enrolled using previously described eligibility 
criteria [17–19, 22, 23]. Study subjects for the vaccinations using 
rDENV1Δ30, rDENV2/4Δ30, rDENV3Δ30/31, and rDENV4Δ30 
were enrolled using study protocols CIR-229, CIR-250, CIR-257, 
and CIR-256, respectively, registered at ClinicalTrials.gov as study 
numbers NCT00473135 [21], NCT00920517, NCT00831012, 
and NCT00919178, respectively (https://clinicaltrials.gov). 
Studies were double-blinded, placebo-controlled phase I trials to 
evaluate the safety, immunogenicity, and infectivity of low-dose 
(10 plaque-forming units) live attenuated monovalent DENV 
vaccines [24]. Serum samples that were collected 6–7.5 months 
after vaccination with a monovalent vaccine were analyzed in de-
pletion and neutralization studies (Table 1).
Monovalent DENV Vaccine Strains
Attenuated strains of DENV1 (Westpac 74), and DENV4 (DENV4 
virus strain 814669, Dominica, 1981), were achieved by deleting 
30 nucleotides from the 3′ untranslated region (UTR), creating 
rDENV1Δ30 and rDENV4Δ30 [18, 23, 24]. DENV3 (Sleman/78) 
required 2 separate deletions (30 and 31 nucleotides) in the 3′ UTR 
for appropriate attenuation for human use DENVΔ30/31 [18, 
24, 28]. DENV2/4Δ30 is a chimeric virus in which the DENV2 
prM and E genes (New Guinea C [NGC]) replace those of vac-
cine candidate DENV4Δ30 [19, 24, 29]. Vaccines were produced 
for human administration using current Good Manufacturing 
Practices at either Charles River Laboratories (rDENV1Δ30 and 
rDENV2/4Δ30) or Meridian Life Sciences (rDENV3Δ30/31). 
Table 1. Description of Serum Samples Used for Characterization, Collected 180 or 222 Days Postchallenge
Sample Sample ID Days PI Sample Sample ID Days PI
DENV1 monovalent samples 229.01.01 180 DENV2 monovalent samples 250.01.03 180
229.01.03 180 250.01.07 180
229.01.05 180 250.01.13 180
229.01.22 180 250.01.17 180
229.01.57 180 250.01.24 180
229.02.39 222 250.01.02 180
229.02.43 222 250.01.05 180
229.02.44 222 250.01.10 180
229.02.49 222 250.01.11 180
229.02.52 222 250.01.15 180
DENV3 monovalent samples 257.01.01 180 DENV4 monovalent samples 256.01.36 180
257.01.02 180 256.01.38 180
257.01.16 180 256.01.46 180
257.03.49 180 256.01.57 180
257.03.45 180 256.01.68 180
257.03.47 180 256.01.51 180




Abbreviations: DENV, dengue virus; ID, identifier; PI, postinfection.
L-15 medium (Cambrex Bioscience) was used to dilute the vac-
cine viruses immediately prior to vaccination. Vaccine virus titers 
were determined using a standard plaque assay [24].
Wild-Type and Recombinant DENVs
For laboratory studies, viruses were propagated in C6/36 insect 
cells or Vero-81 mammalian cells as previously described [30]. 
DENV1 (American genotype; strain West Pac74), DENV2 
(Asian genotype; strain S-16803), DENV3 (Asian genotype; 
strain CH-53489), and DENV4 (American genotype; strain 
TVP-376) were used to produce antigen for enzyme-linked 
immunosorbent assays (ELISAs) and antibody depletion stud-
ies. Envelope protein epitope transplant or knockout recom-
binant DENVs were created using infectious clone systems of 
the 4 DENV serotypes (DENV1 West Pac 74; DENV2 S-16803; 
DENV3 Sri Lanka 89; and DENV4 Sri Lanka 92). Recombinant 
viruses were constructed using the same 4–complementary 
DNA (cDNA) cloning strategy previously used to create wild-
type (WT) DENV infectious clones [11, 30, 31]. The full-length 
cDNA was transcribed into genome-length RNAs using T7 
polymerase. Recombinant genome-length RNA was electropo-
rated into C6/36 cells, and cell culture supernatant containing 
viable virus was harvested. Recovered virus was sequenced to 
confirm identity and stored at −80°C. The recombinant viruses 
used for epitope mapping are listed in Supplementary Table 2.
Whole Virus Depletion of DENV-Specific Antibodies From Monovalent 
Vaccine Immune Sera
Purified DENV was absorbed onto 4.5-μm-diameter Polybead 
polystyrene microspheres (Polysciences, catalog number 
17135-5) at a bead (microliters) to ligand (micrograms) ratio of 
5:2. Polystyrene beads were washed 3 times with 0.1 M borate 
buffer (pH 8.5) and incubated with the relevant purified DENV 
overnight at room temperature. Control beads were incubated 
overnight with an equivalent amount of bovine serum albumin 
(BSA). The control and virus-adsorbed beads were blocked 
with BSA (10  mg/mL)–borate buffer for 30 minutes at room 
temperature and washed 4 times with phosphate-buffered 
saline (PBS). DENV-specific antibodies were depleted from 
human monovalent vaccine sera by incubating virus-adsorbed 
beads with human sera diluted 1:10 in 1× PBS for 1 hour at 37°C 
with end-over-end mixing. Samples were subjected to at least 3 
sequential rounds of depletions before successful removal of the 
respective antibodies was confirmed by ELISA.
ELISA
Initial titration ELISAs were performed to determine the 
amount of antigen needed to fully deplete the sera from the 
respective serotype as previously described [27].
DENV Neutralization Assay
Human sera or MAbs were serially diluted 3-fold and mixed 
with sufficient virus to cause 15% infection in U937 cells 
expressing dendritic cell-specific Intercellular adhesion mol-
ecule-3-Grabbing Non-Integrin (U937+DC-SIGN) or 50 foci 
per well in Vero-81 cells. Assays were performed as previously 
described by our group [32, 33]. Using the 50% neutraliza-
tion (Neut50) titers, the percentage of cross-reactive (CR) and 
type-specific (TS) nAbs against each serotype were calculated 
using the following formulas:
%CR Neutralizing Abs =
%TS
ï
∆ in Neut50 after heterologous serotype depletion
∆ in Neut50 after homologus serotype depletion
ò
x 100
%TS Neutralizing Abs = 100 − % of CR Abs.
Statistical Analysis
Nonparametric Kruskal–Wallis Dunn multiple comparisons 
tests were performed to analyze the differences in mean per-
centage of type-specific responses and also the mean level 
of type-specific responses against the 4 serotypes. Similarly, 
nonparametric Kruskal–Wallis Dunn multiple comparisons 
test was also used for the epitope mapping data to determine 
the loss or gain of neutralization to the recombinant chimeric 
viruses compared to the parental backbone viruses.
RESULTS
NIH Monovalent DENV Vaccines Induce Type-Specific nAbs
We have previously described the overall safety and immuno-
genicity of each monovalent vaccine component among flavi-
virus-naive subjects who received a single dose of the vaccine 
[18, 19, 21–23]. From these studies, we obtained blood from 
20 individuals (5 individuals per serotype) 6 months after vac-
cination to perform antibody depletions and measure levels 
of serotype-specific nAbs. Polystyrene beads coated with the 
homotypic (serotype corresponding to the monovalent vac-
cine) or heterotopic (serotype other than the monovalent vac-
cine component) purified dengue virions were incubated with 
the immune sera to deplete specific populations of antibodies 
as previously described [27]. Following monovalent vaccina-
tion, depletion with the homologous serotype results in the 
removal of all DENV-specific antibody in the sample, whereas 
depletion with heterologous DENV serotypes results in the 
removal of serotype cross-reactive antibodies, while retain-
ing type-specific antibodies to the monovalent vaccine com-
ponent. Antibody depletion against the relevant antigens was 
confirmed by ELISA before performing DENV neutraliza-
tion assays (Supplementary Figures 1–4). For example, when 
a DENV1 monovalent serum sample from subject 229.02.52 
was depleted using DENV1 antigen, ELISA confirmed loss 
of all DENV binding (type-specific and cross-reactive) anti-
bodies and a loss of DENV1 nAbs (Supplementary Figure 
1). Depleting DENV1 vaccine sera with heterotypic DENV2 
antigen led to the removal of serotype–cross-reactive but not 
DENV1 type-specific antibodies. DENV1 was efficiently neu-
tralized after removal of cross-reactive antibodies, demon-
strating that type-specific antibodies were mainly responsible 
for neutralization (Supplementary Figure 1). Across the 5 sub-
jects who received the monovalent DENV1 vaccine, on average 
84% of DENV1 neutralization was mediated by type-spe-
cific antibodies (Figure 1A). Antibody depletion studies also 
demonstrated that type-specific antibodies were responsible 
for 75%, 97.6%, and 84% of DENV2, 3, and 4 monovalent 
vaccine–induced nAb responses, respectively (Figure 1A, and 
Supplementary Figures 2–4). The net type-specific neutral-
ization titers (Figure 1B) show that all subjects maintained 
type-specific neutralization titers following depletion.
Chimeric Recombinant DENV to Map Serotype 1 nAb Responses
Human monoclonal antibody (hMAb) 1F4 is a type-specific, 
strongly neutralizing Ab [6] that has been mapped to a com-
plex epitope that includes EDI and the hinge region between 
EDI and EDII [34]. To measure levels of DENV1 type-specific 
antibodies directed to this epitope, we constructed recombi-
nant (r) DENV2 (Figure 2A) and DENV3 (Figure 2B) strains 
displaying the DENV1 1F4 epitope. The 1F4 epitope was trans-
planted by changing 30 amino acids in DENV2 (Figure 2A) and 
21 amino acids in DENV3 (Figure 2B) to DENV1 residues to 
create rDENV2/1 and rDENV3/1 chimeras. Both rDENV2/1 
and rDENV3/1 were bound and neutralized by 1F4 (Figure 
2C), demonstrating structural and functional transplantation 
of the epitope. The hMAb 14C10 is another DENV1 type-spe-
cific, strongly neutralizing Ab that binds to a quaternary struc-
ture epitope on EDI that overlaps with the 1F4 epitope [10, 13]. 
The DENV3/1, but not the DENV2/1 chimera, was neutralized 
by 14C10, demonstrating display of both the 1F4 and 14C10 
epitopes on this recombinant virus (Figure 2C). The DENV2/1 
strain was neutralized by DENV2 type-specific hMAb 2D22, 
which has an epitope on EDIII that does not overlap with the 
footprint of 1F4 (Figure 2C). The DENV3/1 strain was no 
longer recognized by DENV3 type-specific hMAb 5J7, which 
has an epitope that overlaps with the 1F4 epitope (Figure 2C). 
All the WT and recombinant viruses displayed similar neu-
tralization sensitivity to the pan-dengue serotype neutralizing 
hMAb EDE C10 (Figure 2C), indicating overall preservation of 
structure between WT and recombinant strains.
Mapping Type-Specific nAb Responses Induced by Each Monovalent 
DENV Vaccine
Using the panel of WT and epitope transplant recombinant 
DENVs, we mapped the specificity of type-specific nAbs induced 
by NIH monovalent vaccines at day 180 or 222 after vaccination 
(Figure 3, Supplementary Figure 5, and Supplementary Table 
1). The neutralization assays with the WT and recombinant 
DENVs were performed using U937+DC-SIGN cells (Figure 
3A–D) [35] and Vero-81 cells (Supplementary Figure 5A–D), 
which are widely used to evaluate vaccine responses.
In the U937+DC-SIGN neutralization assay, the DENV1 
monovalent sera neutralized DENV1 but not DENV2 and 
DENV3 (Figure 3A). The rDENV2/1 and rDENV3/1 strains 
were neutralized at levels comparable to WT DENV 1, demon-
strating that the region defined by the hMAb 1F4 was a major 
target of vaccine-induced type-specific nAbs (Figure 3A). The 
tracking of DENV1 nAbs was more consistent across individuals 




















































































































































Figure 1. Proportion and level of homotypic (type-specific) neutralizing antibodies (nAbs) to the serotype component in each of the monovalent samples. Antibody depletion 
assays were used to determine the proportions of dengue virus (DENV) type-specific (homotypic) antibodies induced by the serotype component of the monovalent vaccine. A, 
Each data point depicts the percentage of the total nAb response to the serotype component in the monovalent vaccine attributed to type-specific antibodies. The horizontal 
bar shows the geometric mean titers and 95% confidence intervals (CIs). There was no significant difference in the mean proportion of type-specific antibodies contributing to 
neutralization for the serotype component in each monovalent sample. B, Each data point represents the absolute level of homotypic nAb to the serotype component in each 
of the monovalent samples (eg, the 50% neutralization titer against DENV1 in DENV1 monovalent samples). The horizontal bar shows the geometric mean titers and 95% CIs. 
The dotted line shows the limit of detection value of 5. Abbreviations: DENV, dengue virus; nAbs, neutralizing antibodies; ns, not significant.
demonstrating the impact of the backbone sequence on epitope 
display (Figure 3A). In the Vero-81 cell–based neutralization 
assay, the DENV1 monovalent vaccine sera efficiently neutral-
ized DENV1 and demonstrated low-level cross-neutralization 
of DENV2 and DENV3 (Supplementary Figure 5A). Moreover, 
in this assay we observed no evidence for epitope-specific 
tracking with the rDENV2/1 or rDENV3/1 strains, although 
there was a trend toward tracking with rDENV2/1 that did not 
reach statistical significance (Supplementary Figure 5A).
The subjects who received the monovalent DENV2 vaccine 
had high levels of nAbs to DENV2 and low levels of cross-neu-
tralizing Abs to DENV1 and DENV4 with both cell lines (Figure 
3B and Supplementary Figure 5B). The recombinant DENV2/1 
strain was neutralized at levels comparable to the WT DENV2 
strain, indicating that EDI was not the main target of DENV2 
vaccine–induced nAbs (Figure 3B and Supplementary Figure 
5B). The recombinant DENV4/2 strain containing EDIII 
from DENV2 was efficiently neutralized by subjects who re-
ceived the DENV2 vaccine in the Vero-81 cell–based assay 
(Supplementary Figure 5B), confirming our previous obser-
vations that the DENV2-induced nAbs targeted type-specific 
epitopes centered on EDIII [11]. Due to limited availability of 
sample volume, we were only able to test 4 monovalent DENV2 
samples in the U937+DC-SIGN assay (Figure 3B). While we 
observed a trend of DENV2 nAb tracking with the rDENV4/2 
virus with these cells, the difference did not reach statistical sig-
nificance (Figure 3B).
The subjects who received the monovalent DENV3 vac-
cine had the highest levels of nAbs to this serotype and low 
levels of cross-neutralizing antibodies to DENV1 or DENV4 
depending on the cell type used for the assay (Figure 3C and 
Supplementary Figure 5C). No appreciable loss of DENV3 
neutralization was observed with the DENV3/1 virus, suggest-
ing that this region was not a major target of vaccine-induced 
DENV3 nAbs. The previously described rDENV4/3, displaying 
the DENV3 type-specific, strongly neutralizing hMAb 5J7 qua-
ternary structure epitope centered on the hinge region between 
EDI and EDII [36, 37], was not significantly neutralized by vac-
cine immune sera, demonstrating that the transplanted epitope 
was not a major target of type-specific nAbs (Figure 3C and 
Supplementary Figure 5C). We noted a modest gain of DENV3 
nAbs in 2 subjects, indicating that the DENV3 vaccine can 
induce low levels of antibodies that track with this epitope in 
some people (Figure 3C).
When mapping the DENV4 monovalent vaccine–induced 
response, we used the DENV4/2 and DENV4/3 (Supplementary 
Table 1) loss-of-function mutants. Subjects who received the 
DENV4 vaccine strongly neutralized DENV4 and displayed 
low to no cross-neutralizing antibodies to DENV2 and DENV3 






























Amino acid residue changes in 1F4 (numbering within envelope protein)
Amino acid residue changes in 1F4 (numbering within envelope protein)
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Figure 2. Characterization of dengue virus (DENV) serotype 1, 1F4 recombinant DENV used for mapping the DENV1 responses. Sequence alignments of DENV2/1 (A) 
and DENV3/1 (B). C, Monoclonal antibody neutralization of DENV2/1 and DENV3/1 compared to each parental strain in the U937+DC-SIGN assay. icDENV indicates DENV 
infectious clone.
The recombinant DENV4/2 strain was efficiently neutral-
ized by the vaccine sera at levels comparable to WT DENV4, 
indicating that EDIII was not a major target of DENV4 vac-
cine–induced nAbs (Figure 3D and Supplementary Figure 
5D). DENV4 vaccine sera poorly neutralized the recombinant 
DENV4/3 strain compared to the parental DENV4 (Figure 3D) 
in the U937+DC-SIGN cell assay, indicating that some DENV4 
nAbs target epitopes near the hinge between EDI and EDII. 
The loss of DENV4 neutralization was not observed when the 
DENV4/3 strain was used in the Vero cell assay, indicating the 
importance of tracking epitope specific responses with dif-
ferent cell lines.
DISCUSSION
The leading tetravalent live attenuated DENV vaccines aim 
to stimulate balanced protective immune responses to all 4 
DENV serotypes simultaneously. The preclinical and early clin-
ical development of these vaccines has been largely guided by 
the ability of vaccines to induce nAbs to each DENV serotype 
because nAbs have been correlated with vaccine efficacy [25, 
27, 38]. However, the first tetravalent live DENV vaccine to 
complete phase 3 efficacy trials has demonstrated that the mere 
presence of nAb to a particular serotype is not sufficient to 
protect people from infection and disease [27]. Data from vac-
cine trials and other studies point to both the level and quality 
of nAbs playing a role in durable protective immunity [27]. 
Among people exposed to primary DENV infections, nAbs 
targeting serotype-specific epitopes are strongly correlated with 
protection against the homologous serotype [39]. Herein, we 
evaluated the quality of nAbs induced by the NIH monovalent 
vaccine components in dengue-naive individuals.
Flavivirus-naive subjects who received each monovalent vac-
cine developed high levels of nAbs to the vaccine-matched sero-
type and lower levels to the other serotypes. Antibody depletion 
assays established that 70%–90% of nAb response was directed 
to type-specific epitopes on the vaccine-matched serotype. The 
DENV3 monovalent vaccine virus elicited the highest propor-









































































































































































Figure 3. The dengue virus (DENV) serotype 1–4 vaccine strains induce varying levels of type-specific responses against known neutralizing epitopes. Neutralization assays 
were performed in the U937+DC-SIGN flow-based microneutralization assay. A, DENV1 monovalent vaccine. B, DENV2 monovalent vaccine. C, DENV 3 monovalent vaccine. 
D, DENV4 monovalent vaccine. Each color represents a single sample and the neutralization of each virus (x-axis). Bars indicate the geometric mean titers and 95% confidence 
intervals of the grouped samples. P values are reported between the parental backbone and recombinant DENV strains. Abbreviations: DENV, dengue virus; Neut50, 50% 
neutralization titer; ns, not significant.
proportions elicited by the DENV1 and DENV4 monovalent 
vaccines; the lowest proportion of type-specific antibodies was 
elicited by the DENV2 monovalent vaccine. Having established 
that each vaccine component is capable of eliciting a type-spe-
cific neutralizing response, it will be interesting and important 
to evaluate if these type-specific responses are preserved when 
the 4 components are injected as a tetravalent formulation.
We determined if vaccine-induced type-specific antibodies 
recognized known immunodominant nAb epitopes on each 
serotype. This required the assembly of 2 novel recombinant 
chimeric viruses, DENV2/1 and DENV3/1, that display the 
DENV1 1F4 neutralizing epitope on a heterologous serotype 
backbone. While both recombinant viruses were recognized 
by hMAb 1F4, the DENV3/1 chimera was also recognized by 
the DENV1-specific hMAb 14C10, which has an epitope that 
overlaps with 1F4. The DENV3/1 chimera was not neutralized 
by DENV3 type-specific hMAb 5J7, indicating that the slight 
overlap between the DENV1 1F4 and DENV3 5J7 epitopes 
resulted in the disruption of the 5J7 epitope. The DENV1 mon-
ovalent vaccine–induced antibody response that  tracked with 
the 1F4 epitope displayed on both DENV2/1 and 3/1 viruses in 
the neutralization assay with U937+DC-SIGN–expressing cells 
and also displayed a trend of tracking with the 1F4 epitope in 
the Vero cell–based assay.
The type-specific nAbs induced by the DENV2 monovalent 
vaccine tracked well with the recombinant DENV4/2 EDIII 
chimera, confirming our previous observations that the vaccine 
induces a response that tracks with EDIII [32].
The hMAb 5J7 is the only DENV3 type-specific human nAb 
that has been characterized to date [6, 12]. The DENV3 vac-
cine type-specific responses did not track with this epitope in 
both gain-of-function (DENV4/3 virus displaying 5J7 epitope) 
or loss-of-function (DENV3/1 virus) neutralization assays. Our 
results indicate that other epitopes, yet to be fully described, are 
the major targets of the DENV3 type-specific response. Indeed, 
recent studies demonstrate that the 5J7 epitope is not the major 
target of nAbs in people exposed to primary DENV3 infections 
as well [36].
The DENV4 monovalent vaccine response appears to tar-
get epitopes centered near the hinge region between EDI/
EDII because the DENV4/3 chimera was poorly neutralized 
compared to WT DENV4 in the neutralization assay using 
U937+DC-SIGN cells. Indeed, 2 strongly neutralizing hMAbs 
(DV4-126 and DV4-131) isolated from individuals infected 
with DENV4 have been mapped to this region on DENV4, 
implicated as a target for vaccine-induced nAbs [14].
We used both Vero and U937+DC-SIGN cells to map vac-
cine-induced nAb responses because of recent data from vaccine 
trials indicating that titers measured with the Vero cell assay may 
not be sufficient for protection [18]. Indeed, we observed inter-
esting differences between Vero and U937+DC-SIGN cells with 
monovalent vaccine immune sera. The DENV1 and DENV4 
monovalent vaccine responses tracked with known epitopes 
on EDI and the EDI/EDII hinge region in the U937+DC-SIGN 
assay but not the traditional Vero cell–based assay. Numerous 
factors may be contributing to this discordance, noting that the 
entry receptor for Vero cells remains unknown, but is thought 
to engage the E glycoprotein EDIII region, whereas DC-SIGN–
mediated entry is via binding to the N-linked glycan on EDII 
[40]. In addition, as some antibodies can bind to DENVs and 
promote Fc receptor mediated entry and infection of cells, the 
presence of Fc receptors on U937 but not Vero cells may also 
account for the observed differences. We recently observed that 
DENV1 strains circulating in people are fully mature, whereas 
the same strains passaged on laboratory cell lines are less effi-
ciently processed and released as partially mature virions [41]. 
Differences in the maturation state of DENVs can also alter 
antibody neutralization in a cell type–dependent manner [42].
Overall, this study continues to apply new pioneering approaches 
and assays to evaluate the quality of nAbs elicited by individual 
components of a live attenuated DENV tetravalent vaccine. More 
significantly, we also mapped vaccine type–specific neutralizing 
responses to epitopes that are also targeted during natural infec-
tions. Importantly, these studies provide valuable insights about 
the quality of the nAb responses elicited by the monovalent vac-
cines in isolation. Although these data predict that each individ-
ual component is primed to elicit robust type-specific responses, 
comparative studies in volunteers receiving the tetravalent vaccine 
will identify whether certain components elicit immunodominant 
epitope-specific or balanced responses across all 4 components. 
Large-sized human clinical efficacy trials will actually show if 
these qualitative trends are also reflected on a larger population in 
endemic regions receiving tetravalent vaccines.
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